| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A centralised multidisciplinary clinic approach for germ cell tumours
|
Crawford, S.M.
|
|
|
29 |
11 |
p. 2263-2264
|
artikel
|
| 2 |
Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics
|
Nikanjam, M.
|
|
|
29 |
11 |
p. 2192-2199
|
artikel
|
| 3 |
Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?
|
Thai, A.A.
|
|
|
29 |
11 |
p. 2160-2162
|
artikel
|
| 4 |
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
|
Gadgeel, S.
|
|
|
29 |
11 |
p. 2214-2222
|
artikel
|
| 5 |
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
|
Long, G.V.
|
|
|
29 |
11 |
p. 2208-2213
|
artikel
|
| 6 |
Corrections to “Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results”
|
Aparicio, T.
|
|
|
29 |
11 |
p. 2270
|
artikel
|
| 7 |
Corrections to “Capturing intra-tumor genetic heterogeneity byde novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle”
|
De Mattos-Arruda, L
|
|
|
29 |
11 |
p. 2268
|
artikel
|
| 8 |
“Corrections to Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC”
|
Knox, J.J.
|
|
|
29 |
11 |
p. 2269
|
artikel
|
| 9 |
Corrections to “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness”
|
Czuczman, M.S.
|
|
|
29 |
11 |
p. 2271
|
artikel
|
| 10 |
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
|
Smoragiewicz, M.
|
|
|
29 |
11 |
p. 2175-2182
|
artikel
|
| 11 |
Developing prognostic models for advanced prostate cancer when the goal line keeps changing
|
Fu, S.Y.F.
|
|
|
29 |
11 |
p. 2155-2157
|
artikel
|
| 12 |
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
|
Armstrong, A.J.
|
|
|
29 |
11 |
p. 2200-2207
|
artikel
|
| 13 |
Editorial board
|
|
|
|
29 |
11 |
p. ii-iii
|
artikel
|
| 14 |
ESCAT: a step in the right direction
|
Silver, A.J.
|
|
|
29 |
11 |
p. 2266-2267
|
artikel
|
| 15 |
How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies
|
Ascierto, P.A.
|
|
|
29 |
11 |
p. 2157-2160
|
artikel
|
| 16 |
Human endogenous retroviruses and their implication for immunotherapeutics of cancer
|
Attermann, A.S.
|
|
|
29 |
11 |
p. 2183-2191
|
artikel
|
| 17 |
Immunological differences between primary and metastatic breast cancer
|
Szekely, B.
|
|
|
29 |
11 |
p. 2232-2239
|
artikel
|
| 18 |
Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers
|
Głodzik, D.
|
|
|
29 |
11 |
p. 2223-2231
|
artikel
|
| 19 |
Neoadjuvant rectal score: run with the hare and hunt with the hounds
|
Sclafani, F.
|
|
|
29 |
11 |
p. 2261-2262
|
artikel
|
| 20 |
Oncogenes expand during evolution to withstand somatic amplification
|
Wang, X.
|
|
|
29 |
11 |
p. 2254-2260
|
artikel
|
| 21 |
Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer
|
Taniguchi, Y.
|
|
|
29 |
11 |
p. 2262-2263
|
artikel
|
| 22 |
Reply to the letter to the editor ‘A centralised multidisciplinary clinic approach for germ cell tumours’ by Crawford
|
Albany, C.
|
|
|
29 |
11 |
p. 2264-2265
|
artikel
|
| 23 |
Reply to the letter to the editor ‘Body mass index and 20-specific cancers—re-analyses of dose–response meta-analyses of observational studies’ by Markozannes et al.
|
Choi, E.K.
|
|
|
29 |
11 |
p. 2265-2266
|
artikel
|
| 24 |
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
|
Colevas, A.D.
|
|
|
29 |
11 |
p. 2247-2253
|
artikel
|
| 25 |
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
|
Marabelle, A.
|
|
|
29 |
11 |
p. 2163-2174
|
artikel
|
| 26 |
Table of Contents
|
|
|
|
29 |
11 |
p. iv-v
|
artikel
|
| 27 |
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial
|
Mooi, J.K.
|
|
|
29 |
11 |
p. 2240-2246
|
artikel
|
Tijdschrift beschrijving